Recombinant birch pollen allergoid (folding variant) - Allergopharma

Drug Profile

Recombinant birch pollen allergoid (folding variant) - Allergopharma

Alternative Names: rBet v1 - folding variant; rBet v1-FV

Latest Information Update: 15 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomay
  • Developer Allergopharma
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 01 Sep 2011 Allergopharma completes a phase II trial in Seasonal allergic rhinitis in Germany (NCT01490411)
  • 24 Aug 2010 Phase II development is ongoing in Sweden
  • 24 Aug 2010 Phase III development is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top